Metagenomics Applied to the Respiratory Mycobiome in Cystic Fibrosis.
Cystic fibrosis mycobiome
Fungi
Next-generation sequencing
Journal
Mycopathologia
ISSN: 1573-0832
Titre abrégé: Mycopathologia
Pays: Netherlands
ID NLM: 7505689
Informations de publication
Date de publication:
12 Sep 2024
12 Sep 2024
Historique:
received:
10
05
2024
accepted:
21
08
2024
medline:
12
9
2024
pubmed:
12
9
2024
entrez:
12
9
2024
Statut:
epublish
Résumé
Cystic fibrosis (CF) is a genetic disorder characterized by chronic microbial colonization and inflammation of the respiratory tract (RT), leading to pulmonary exacerbation (PEx) and lung damage. Although the lung bacterial microbiota has been extensively studied, the mycobiome remains understudied. However, its importance as a contributor to CF pathophysiology has been highlighted. The objective of this review is to provide an overview of the current state of knowledge regarding the mycobiome, as described through NGS-based studies, in patients with CF (pwCF).Several studies have demonstrated that the mycobiome in CF lungs is a dynamic entity, exhibiting a lower diversity and abundance than the bacterial microbiome. Nevertheless, the progression of lung damage is associated with a decrease in fungal and bacterial diversity. The core mycobiome of the RT in pwCFs is mainly composed of yeasts (Candida spp., Malassezia spp.) and molds with lower abundance. Some fungi (Aspergillus, Scedosporium/Pseudallescheria) have been demonstrated to play a role in PEx, while the involvement of others (Candida, Pneumocystis) remains uncertain. The "climax attack" ecological model has been proposed to explain the complexity and interplay of microbial populations in the RT, leading to PEx and lung damage. NGS-based studies also enable the detection of intra- and interkingdom correlations between fungi and bacteria. Further studies are required to ascertain the biological and pathophysiological relevance of these correlations. Finally, with the recent advent of CFTR modulators, our understanding of the pulmonary microbiome and mycobiome in pwCFs is about to change.
Identifiants
pubmed: 39264513
doi: 10.1007/s11046-024-00887-6
pii: 10.1007/s11046-024-00887-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
82Informations de copyright
© 2024. The Author(s).
Références
Elborn JS. Cystic fibrosis. Lancet. 2016;388:2519–31.
pubmed: 27140670
doi: 10.1016/S0140-6736(16)00576-6
Vaincre la Mucoviscidose. Registre français de la mucoviscidose - Bilan des données 2022. https://www.vaincrelamuco.org/registredelamuco . 2022.
Rossi GA, Morelli P, Galietta LJ, Colin AA. Airway microenvironment alterations and pathogen growth in cystic fibrosis. Pediatr Pulmonol. 2019;54:497–506.
pubmed: 30620146
doi: 10.1002/ppul.24246
Flume PA, VanDevanter DR. Cystic fibrosis: definition, severity and impact of pulmonary exacerbations. In: Burgel P-R, Contoli M, López-Campos JL, editors. Acute Exacerbations of Pulmonary Diseases. European Respiratory Society; 2017. p. 25–37. https://doi.org/10.1183/2312508X.10015716 .
doi: 10.1183/2312508X.10015716
Thornton CS, Parkins MD. Microbial epidemiology of the cystic fibrosis airways: past, present, and future. Semin Respir Crit Care Med. 2023;44:269–86.
pubmed: 36623820
doi: 10.1055/s-0042-1758732
Tracy MC, Moss RB. The myriad challenges of respiratory fungal infection in cystic fibrosis. Pediatr Pulmonol. 2018;53:S75-85.
pubmed: 29992775
doi: 10.1002/ppul.24126
Schwarz C, Hartl D, Eickmeier O, Hector A, Benden C, Durieu I, et al. Progress in definition, prevention and treatment of fungal infections in cystic fibrosis. Mycopathologia. 2018;183:21–32.
pubmed: 28762125
doi: 10.1007/s11046-017-0182-0
Francis F, Enaud R, Soret P, Lussac-Sorton F, Avalos-Fernandez M. MucoFong investigation group, et al. new insights in microbial species predicting lung function decline in CF: lessons from the MucoFong project. J Clin Med. 2021;10:3725.
pubmed: 34442021
pmcid: 8396880
doi: 10.3390/jcm10163725
Delhaes L, Touati K, Faure-Cognet O, Cornet M, Botterel F, Dannaoui E, et al. Prevalence, geographic risk factor, and development of a standardized protocol for fungal isolation in cystic fibrosis: results from the international prospective study “MFIP.” J Cyst Fibros. 2019;18:212–20.
pubmed: 30348610
doi: 10.1016/j.jcf.2018.10.001
Chotirmall SH, O’Donoghue E, Bennett K, Gunaratnam C, O’Neill SJ, McElvaney NG. Sputum Candida albicans presages FEV
pubmed: 20472859
doi: 10.1378/chest.09-2996
Gileles-Hillel A, Shoseyov D, Polacheck I, Korem M, Kerem E, Cohen-Cymberknoh M. Association of chronic Candida albicans respiratory infection with a more severe lung disease in patients with cystic fibrosis. Pediatr Pulmonol. 2015;50:1082–9.
pubmed: 26383963
doi: 10.1002/ppul.23302
Delhaes L, Monchy S, Frealle E, Hubans C, Salleron J, Leroy S, et al. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community-implications for therapeutic management. PLoS ONE. 2012;7:e36313.
pubmed: 22558432
pmcid: 3338676
doi: 10.1371/journal.pone.0036313
Botterel F, Angebault C, Cabaret O, Stressmann FA, Costa J-M, Wallet F, et al. Fungal and bacterial diversity of airway microbiota in adults with cystic fibrosis: concordance between conventional methods and ultra-deep sequencing, and their practical use in the clinical laboratory. Mycopathologia. 2018;183:171–83.
pubmed: 28766039
doi: 10.1007/s11046-017-0185-x
Kramer R, Sauer-Heilborn A, Welte T, Guzman CA, Abraham W-R, Höfle MG. Cohort study of airway mycobiome in adult cystic fibrosis patients: differences in community structure between fungi and bacteria reveal predominance of transient fungal elements. J Clin Microbiol. 2015;53:2900.
pubmed: 26135861
pmcid: 4540938
doi: 10.1128/JCM.01094-15
Soret P, Vandenborght L-E, Francis F, Coron N, Enaud R, Avalos M, et al. Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis. Sci Rep. 2020;10:3589.
pubmed: 32108159
pmcid: 7046743
doi: 10.1038/s41598-020-60015-4
Thornton CS, Acosta N, Surette MG, Parkins MD. Exploring the cystic fibrosis lung microbiome: making the most of a sticky situation. J Pediatric Infect Dis Soc. 2022;11:S13-22.
pubmed: 36069903
pmcid: 9451016
doi: 10.1093/jpids/piac036
Cuthbertson L, Felton I, James P, Cox MJ, Bilton D, Schelenz S, et al. The fungal airway microbiome in cystic fibrosis and non-cystic fibrosis bronchiectasis. J Cyst Fibros. 2021;20:295–302.
pubmed: 32540174
pmcid: 8048771
doi: 10.1016/j.jcf.2020.05.013
McDermott G, Walsh A, Crispie F, Frost S, Greally P, Cotter PD, et al. Insights into the adolescent cystic fibrosis airway microbiome using shotgun metagenomics. Int J Mol Sci. 2024;25:3893.
pubmed: 38612702
pmcid: 11011389
doi: 10.3390/ijms25073893
Iliev ID, Cadwell K. Effects of intestinal fungi and viruses on immune responses and inflammatory bowel diseases. Gastroenterology. 2021;160:1050–66.
pubmed: 33347881
doi: 10.1053/j.gastro.2020.06.100
Angebault C, Payen M, Woerther P-L, Rodriguez C, Botterel F. Combined bacterial and fungal targeted amplicon sequencing of respiratory samples: does the DNA extraction method matter? PLoS ONE. 2020;15: e0232215.
pubmed: 32343737
pmcid: 7188255
doi: 10.1371/journal.pone.0232215
Huseyin CE, Rubio RC, O’Sullivan O, Cotter PD, Scanlan PD. The Fungal Frontier: a comparative analysis of methods used in the study of the human gut mycobiome. Front Microbiol. 2017;8:1432.
pubmed: 28824566
pmcid: 5534473
doi: 10.3389/fmicb.2017.01432
Angebault C, Ghozlane A, Volant S, Botterel F, d’Enfert C, Bougnoux M-E. Combined bacterial and fungal intestinal microbiota analyses: impact of storage conditions and DNA extraction protocols. PLoS ONE. 2018;13: e0201174.
pubmed: 30074988
pmcid: 6075747
doi: 10.1371/journal.pone.0201174
Gangneux J-P, Guegan H, Vandenborght L-E, Buffet-Bataillon S, Enaud R, Delhaes L. A European ECMM-ESCMID survey on goals and practices for mycobiota characterisation using next-generation sequencing. Mycoses. 2019;62:1096–9.
pubmed: 31498487
doi: 10.1111/myc.12999
Nash AK, Auchtung TA, Wong MC, Smith DP, Gesell JR, Ross MC, et al. The gut mycobiome of the human microbiome project healthy cohort. Microbiome. 2017;5:153.
pubmed: 29178920
pmcid: 5702186
doi: 10.1186/s40168-017-0373-4
Dellière S, Dannaoui E, Fieux M, Bonfils P, Gricourt G, Demontant V, et al. Analysis of microbiota and mycobiota in fungal ball rhinosinusitis: specific interaction between Aspergillus fumigatus and Haemophilus influenza? Journal of Fungi. 2021;7:550.
pubmed: 34356929
pmcid: 8305266
doi: 10.3390/jof7070550
Nahimana A, Francioli P, Blanc DS, Bille J, Wakefield AE, Hauser PM. Determination of the copy number of the nuclear rDNA and beta-tubulin genes of Pneumocystis carinii f. sp. hominis using PCR multicompetitors. J Eukaryot Microbiol. 2000;47:368–72.
pubmed: 11140450
doi: 10.1111/j.1550-7408.2000.tb00062.x
d’Humières C, Salmona M, Dellière S, Leo S, Rodriguez C, Angebault C, et al. The potential role of clinical metagenomics in infectious diseases: therapeutic perspectives. Drugs. 2021. https://doi.org/10.1007/s40265-021-01572-4 .
doi: 10.1007/s40265-021-01572-4
pubmed: 34328626
pmcid: 8323086
Pienkowska K, Pust M-M, Gessner M, Gaedcke S, Thavarasa A, Rosenboom I, et al. The cystic fibrosis upper and lower airway metagenome. Microbiol Spectr. 2023;11: e0363322.
pubmed: 36892308
doi: 10.1128/spectrum.03633-22
Rodriguez C, Jary A, Hua C, Woerther P-L, Bosc R, Desroches M, et al. Pathogen identification by shotgun metagenomics of patients with necrotizing soft-tissue infections. Br J Dermatol. 2020;183:105–13.
pubmed: 31610037
doi: 10.1111/bjd.18611
Lind AL, Pollard KS. Accurate and sensitive detection of microbial eukaryotes from whole metagenome shotgun sequencing. Microbiome. 2021;9:58.
pubmed: 33658077
pmcid: 7931531
doi: 10.1186/s40168-021-01015-y
Ubags NDJ, Marsland BJ. Mechanistic insight into the function of the microbiome in lung diseases. Eur Respir J. 2017;50:1602467.
pubmed: 28893867
doi: 10.1183/13993003.02467-2016
Bercusson A, Jarvis G, Shah A. CF fungal disease in the age of CFTR modulators. Mycopathologia. 2021;186:655–64.
pubmed: 33813719
pmcid: 8536598
doi: 10.1007/s11046-021-00541-5
Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med. 2012;18:509–19.
pubmed: 22481418
pmcid: 3577071
doi: 10.1038/nm.2715
Dickson RP, Erb-Downward JR, Huffnagle GB. Homeostasis and its disruption in the lung microbiome. Am J Physiol Lung Cell Mol Physiol. 2015;309:L1047–55.
pubmed: 26432870
pmcid: 4652146
doi: 10.1152/ajplung.00279.2015
Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest. 2002;109:317–25.
pubmed: 11827991
pmcid: 150856
doi: 10.1172/JCI0213870
Granchelli AM, Adler FR, Keogh RH, Kartsonaki C, Cox DR, Liou TG. Microbial interactions in the cystic fibrosis airway. J Clin Microbiol. 2018;56:e00354-e418.
pubmed: 29769279
pmcid: 6062800
doi: 10.1128/JCM.00354-18
Renner S, Nachbaur E, Jaksch P, Dehlink E. Update on respiratory fungal infections in cystic fibrosis lung disease and after lung transplantation. Journal of Fungi. 2020;6:381.
pubmed: 33371198
pmcid: 7766476
doi: 10.3390/jof6040381
Schwarz C, Bouchara J-P, Buzina W, Chrenkova V, Dmeńska H, de la Pedrosa EGG, et al. Organization of patient management and fungal epidemiology in cystic fibrosis. Mycopathologia. 2018;183:7–19.
pubmed: 29098487
doi: 10.1007/s11046-017-0205-x
Engel TGP, Tehupeiory-Kooreman M, Melchers WJG, Reijers MH, Merkus P, Verweij PE. Evaluation of a new culture protocol for enhancing fungal detection rates in respiratory samples of cystic fibrosis patients. J Fungi (Basel). 2020;6:82.
pubmed: 32526938
doi: 10.3390/jof6020082
de Jong CCM, Slabbers L, Engel TGP, Yntema JB, van Westreenen M, Croughs PD, et al. Clinical relevance of Scedosporium spp. and Exophiala dermatitidis in patients with cystic fibrosis: a nationwide study. Med Mycol. 2020;58:859–66.
pubmed: 32030418
pmcid: 7527267
doi: 10.1093/mmy/myaa003
Ravenel K, Guegan H, Gastebois A, Bouchara J-P, Gangneux J-P, Giraud S. Fungal colonization of the airways of patients with cystic fibrosis: the role of the environmental reservoirs. Mycopathologia. 2024;189:19.
pubmed: 38407729
doi: 10.1007/s11046-023-00818-x
van Rhijn N, Coleman J, Collier L, Moore C, Richardson MD, Bright-Thomas RJ, et al. Meteorological factors influence the presence of fungi in the air; A 14-month surveillance study at an adult cystic fibrosis center. Front Cell Infect Microbiol. 2021;11: 759944.
pubmed: 34900752
pmcid: 8662344
doi: 10.3389/fcimb.2021.759944
Ziesing S, Suerbaum S, Sedlacek L. Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center. Med Mycol. 2016;54:781–6.
pubmed: 27364649
doi: 10.1093/mmy/myw035
Psoter KJ, De Roos AJ, Wakefield J, Mayer JD, Rosenfeld M. Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis. BMC Infect Dis. 2017;17:411.
pubmed: 28599639
pmcid: 5466772
doi: 10.1186/s12879-017-2511-9
Vaincre la Mucoviscidose. Registre français de la mucoviscidose - Bilan des données 2016. http://www.vaincrelamuco.org/sites/default/files/registre_francais_de_la_mucoviscidose_-_bilan_2015_v4.pdf . 2016.
Regard L, Martin C, Da Silva J, Burgel P-R. CFTR modulators: current status and evolving knowledge. Semin Respir Crit Care Med. 2023;44:186–95.
pubmed: 36535667
doi: 10.1055/s-0042-1758851
Chesnay A, Bailly É, Cosson L, Flament T, Desoubeaux G. Advent of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis treatment: what consequences on Aspergillus-related diseases? Preliminary insights J Cyst Fibros. 2022;21:1084–5.
pubmed: 36151024
doi: 10.1016/j.jcf.2022.09.007
O’Connor JB, Mottlowitz M, Kruk ME, Mickelson A, Wagner BD, Harris JK, et al. Network analysis to identify multi-omic correlations in the lower airways of children with cystic fibrosis. Front Cell Infect Microbiol. 2022;12: 805170.
pubmed: 35360097
pmcid: 8960254
doi: 10.3389/fcimb.2022.805170
Frayman KB, Armstrong DS, Carzino R, Ferkol TW, Grimwood K, Storch GA, et al. The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis. Thorax. 2017;72:1104–12.
pubmed: 28280235
doi: 10.1136/thoraxjnl-2016-209279
Coburn B, Wang PW, Diaz Caballero J, Clark ST, Brahma V, Donaldson S, et al. Lung microbiota across age and disease stage in cystic fibrosis. Sci Rep. 2015. https://doi.org/10.1038/srep10241 .
doi: 10.1038/srep10241
pubmed: 26047320
pmcid: 4456944
Quittner AL, Sawicki GS, McMullen A, Rasouliyan L, Pasta DJ, Yegin A, et al. Psychometric evaluation of the cystic fibrosis questionnaire-revised in a national sample. Qual Life Res. 2012;21:1267–78.
pubmed: 21993695
doi: 10.1007/s11136-011-0036-z
Hong G, Daniel SG, Lee J-J, Bittinger K, Glaser L, Mattei LM, et al. Distinct community structures of the fungal microbiome and respiratory health in adults with cystic fibrosis. J Cyst Fibros. 2023;22:636–43.
pubmed: 36822979
pmcid: 10440372
doi: 10.1016/j.jcf.2023.02.003
Neu AT, Allen EE, Roy K. Defining and quantifying the core microbiome: challenges and prospects. Proc Natl Acad Sci. 2021;118: e2104429118.
pubmed: 34862327
pmcid: 8713806
doi: 10.1073/pnas.2104429118
Risely A. Applying the core microbiome to understand host–microbe systems. J Anim Ecol. 2020;89:1549–58.
pubmed: 32248522
doi: 10.1111/1365-2656.13229
Enaud R, Vandenborght L-E, Coron N, Bazin T, Prevel R, Schaeverbeke T, et al. The mycobiome: a neglected component in the microbiota-gut-brain axis. Microorganisms. 2018. https://doi.org/10.3390/microorganisms6010022 .
doi: 10.3390/microorganisms6010022
pubmed: 29522426
pmcid: 5874636
Lepesqueur LSS, Tanaka MH, de Lima G MG, Chiba SM, Mota AJ, Santos SF, et al. Oral prevalence and antifungal susceptibility of Candida species in cystic fibrosis patients. Arch Oral Biol. 2020;116:104772.
pubmed: 32474212
doi: 10.1016/j.archoralbio.2020.104772
Ali NABM, Ivan FX, Aogáin MM, Narayana JK, Lee SY, Lim CL, et al. The healthy airway mycobiome in individuals of Asian descent. Chest. 2021;159:544–8.
pubmed: 32926873
doi: 10.1016/j.chest.2020.09.072
Nguyen LDN, Viscogliosi E, Delhaes L. The lung mycobiome: an emerging field of the human respiratory microbiome. Front Microbiol. 2015;6:89.
pubmed: 25762987
pmcid: 4327734
doi: 10.3389/fmicb.2015.00089
Delavy M, Sertour N, Patin E, Le Chatelier E, Cole N, Dubois F, et al. Unveiling Candida albicans intestinal carriage in healthy volunteers: the role of micro- and mycobiota, diet, host genetics and immune response. Gut Microbes. 2023;15:2287618.
pubmed: 38017705
pmcid: 10732203
doi: 10.1080/19490976.2023.2287618
Martínez-Rodríguez S, Friaza V, Girón-Moreno RM, Gallego EQ, Salcedo-Posadas A, Figuerola-Mulet J, et al. Fungal microbiota dynamics and its geographic, age and gender variability in patients with cystic fibrosis. Clin Microbiol Infect. 2023;29:539.e1-539.e7.
pubmed: 36371030
doi: 10.1016/j.cmi.2022.11.001
Armstead J, Morris J, Denning DW. Multi-country estimate of different manifestations of aspergillosis in cystic fibrosis. PLoS ONE. 2014;9: e98502.
pubmed: 24914809
pmcid: 4051580
doi: 10.1371/journal.pone.0098502
Kondori N, Gilljam M, Lindblad A, Jonsson B, Moore ERB, Wenneras C. High rate of Exophiala dermatitidis recovery in the airways of patients with cystic fibrosis is associated with pancreatic insufficiency. J Clin Microbiol. 2011;49:1004–9.
pubmed: 21209163
pmcid: 3067733
doi: 10.1128/JCM.01899-10
Dickson RP, Erb-Downward JR, Freeman CM, McCloskey L, Falkowski NR, Huffnagle GB, et al. Bacterial topography of the healthy human lower respiratory tract. MBio. 2017;8:e02287-e2316.
pubmed: 28196961
pmcid: 5312084
doi: 10.1128/mBio.02287-16
Baxter CG, Moore CB, Jones AM, Webb AK, Denning DW. IgE-mediated immune responses and airway detection of Aspergillus and Candida in adult cystic fibrosis. Chest. 2013;143:1351–7.
pubmed: 23139075
doi: 10.1378/chest.12-1363
Chotirmall SH. Candida albicans in cystic fibrosis: “opening statements presented, let the trial begin.” Pediatr Pulmonol. 2016;51:445–6.
pubmed: 26418834
doi: 10.1002/ppul.23315
d’Enfert C, Kaune A-K, Alaban L-R, Chakraborty S, Cole N, Delavy M, et al. The impact of the fungus-host-microbiota interplay upon Candida albicans infections: current knowledge and new perspectives. FEMS Microbiol Rev. 2021;45:060.
Alam F, Blackburn SA, Davis J, Massar K, Correia J, Tsai H-J, et al. Pseudomonas aeruginosa increases the susceptibility of Candida albicans to amphotericin B in dual-species biofilms. J Antimicrob Chemother. 2023;78:2228–41.
pubmed: 37522316
pmcid: 10477122
doi: 10.1093/jac/dkad228
Alam F, Catlow D, Di Maio A, Blair JMA, Hall RA. Candida albicans enhances meropenem tolerance of Pseudomonas aeruginosa in a dual-species biofilm. J Antimicrob Chemother. 2020;75:925–35.
pubmed: 31865379
doi: 10.1093/jac/dkz514
Santos-Fernandez E, Martin-Souto L, Antoran A, Areitio M, Aparicio-Fernandez L, Bouchara J-P, et al. Microbiota and fungal-bacterial interactions in the cystic fibrosis lung. FEMS Microbiol Rev. 2023;47:029.
doi: 10.1093/femsre/fuad029
Bigot J, Ruffin M, Guitard J, Vellaissamy S, Thorez S, Corvol H, et al. Effect of flagellin pre-exposure on the inflammatory and antifungal response of bronchial epithelial cells to fungal pathogens. J Fungi (Basel). 2022;8:1268.
pubmed: 36547601
doi: 10.3390/jof8121268
Maturu VN, Agarwal R. Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis. Clin Exp Allergy. 2015;45:1765–78.
pubmed: 26177981
doi: 10.1111/cea.12595
Rammaert B, Puyade M, Cornely OA, Seidel D, Grossi P, Husain S, et al. Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European confederation of medical mycology. Transpl Infect Dis. 2019;21: e13141.
pubmed: 31283872
doi: 10.1111/tid.13141
Abdolrasouli A, Bercusson AC, Rhodes JL, Hagen F, Buil JB, Tang AYY, et al. Airway persistence by the emerging multi-azole-resistant Rasamsonia argillacea complex in cystic fibrosis. Mycoses. 2018;61:665–73.
pubmed: 29702751
doi: 10.1111/myc.12789
Zouhair R, Rougeron A, Razafimandimby B, Kobi A, Bouchara J-P, Giraud S. Distribution of the different species of the Pseudallescheria boydii/Scedosporium apiospermum complex in French patients with cystic fibrosis. Med Mycol. 2013;51:603–13.
pubmed: 23461512
doi: 10.3109/13693786.2013.770606
Giraud S, Pihet M, Razafimandimby B, Carrère J, Degand N, Mely L, et al. Geosmithia argillacea: an emerging pathogen in patients with cystic fibrosis. J Clin Microbiol. 2010;48:2381–6.
pubmed: 20463155
pmcid: 2897494
doi: 10.1128/JCM.00047-10
Spahr JE, Love RB, Francois M, Radford K, Meyer KC. Lung transplantation for cystic fibrosis: current concepts and one center’s experience. J Cyst Fibros. 2007;6:334–50.
pubmed: 17418647
doi: 10.1016/j.jcf.2006.12.010
Mills R, Rautemaa-Richardson R, Wilkinson S, Patel L, Maitra A, Horsley A. Impact of airway Exophiala spp. on children with cystic fibrosis. J Cyst Fibros. 2021;20:702–7.
pubmed: 33775601
doi: 10.1016/j.jcf.2021.03.012
Willger SD, Grim SL, Dolben EL, Shipunova A, Hampton TH, Morrison HG, et al. Characterization and quantification of the fungal microbiome in serial samples from individuals with cystic fibrosis. Microbiome. 2014;2:40.
pubmed: 25408892
pmcid: 4236224
doi: 10.1186/2049-2618-2-40
Dmitrijeva M, Kahlert CR, Feigelman R, Kleiner RL, Nolte O, Albrich WC, et al. Strain-resolved dynamics of the lung microbiome in patients with cystic fibrosis. MBio. 2021;12:e02863-e2920.
pubmed: 33688005
pmcid: 8092271
doi: 10.1128/mBio.02863-20
Hernández-Hernández F, Fréalle E, Caneiro P, Salleron J, Durand-Joly I, Accoceberry I, et al. Prospective multicenter study of Pneumocystis jirovecii colonization among cystic fibrosis patients in France. J Clin Microbiol. 2012;50:4107–10.
pubmed: 23015669
pmcid: 3502982
doi: 10.1128/JCM.01974-12
Nevez G, Robert-Gangneux F, Pougnet L, Virmaux M, Belleguic C, Deneuville E, et al. Pneumocystis jirovecii and cystic fibrosis in brittany. France Mycopathologia. 2018;183:81–7.
pubmed: 28688008
doi: 10.1007/s11046-017-0172-2
Gal SL, Héry-Arnaud G, Ramel S, Virmaux M, Damiani C, Totet A, et al. Pneumocystis jirovecii and cystic fibrosis in France. Scand J Infect Dis. 2010;42:225–7.
pubmed: 20085426
doi: 10.3109/00365540903447000
Green HD, Bright-Thomas RJ, Mutton KJ, Guiver M, Jones AM. Increased prevalence of Pneumocystis jirovecii colonisation in acute pulmonary exacerbations of cystic fibrosis. J Infect. 2016;73:1–7.
pubmed: 27189843
doi: 10.1016/j.jinf.2016.05.001
Sing A, Geiger AM, Hogardt M, Heesemann J. Pneumocystis carinii carriage among cystic fibrosis patients, as detected by nested PCR. J Clin Microbiol. 2001;39:2717–8.
pubmed: 11427604
pmcid: 88220
doi: 10.1128/JCM.39.7.2717-2718.2001
Pederiva MA, Wissmann G, Friaza V, Morilla R, de La Horra C, Montes-Cano MA, et al. High prevalence of Pneumocystis jirovecii colonization in Brazilian cystic fibrosis patients. Med Mycol. 2012;50:556–60.
pubmed: 22206262
doi: 10.3109/13693786.2011.645892
Respaldiza N, Montes-Cano MA, Dapena FJ, de la Horra C, Mateos I, Medrano FJ, et al. Prevalence of colonisation and genotypic characterisation of Pneumocystis jirovecii among cystic fibrosis patients in Spain. Clin Microbiol Infect. 2005;11:1012–5.
pubmed: 16307556
doi: 10.1111/j.1469-0691.2005.01276.x
Bonnet P, Le Gal S, Calderon E, Delhaes L, Quinio D, Robert-Gangneux F, et al. Pneumocystis jirovecii in patients with cystic fibrosis: a review. Front Cell Infect Microbiol. 2020;10: 571253.
pubmed: 33117730
pmcid: 7553083
doi: 10.3389/fcimb.2020.571253
Loeffert ST, Melloul E, Dananché C, Hénaff L, Bénet T, Cassier P, et al. Monitoring of clinical strains and environmental fungal aerocontamination to prevent invasive aspergillosis infections in hospital during large deconstruction work: a protocol study. BMJ Open. 2017. https://doi.org/10.1136/bmjopen-2017-018109 .
doi: 10.1136/bmjopen-2017-018109
pubmed: 29175886
pmcid: 5719317
Conrad D, Haynes M, Salamon P, Rainey PB, Youle M, Rohwer F. Cystic fibrosis therapy: a community ecology perspective. Am J Respir Cell Mol Biol. 2013;48:150–6.
pubmed: 23103995
pmcid: 3604065
doi: 10.1165/rcmb.2012-0059PS
Quinn RA, Whiteson K, Lim YW, Zhao J, Conrad D, LiPuma JJ, et al. Ecological networking of cystic fibrosis lung infections. NPJ Biofilms Microbiomes. 2016;2:4.
pubmed: 28649398
pmcid: 5460249
doi: 10.1038/s41522-016-0002-1
Peschel S, Müller CL, von Mutius E, Boulesteix A-L, Depner M. NetCoMi: network construction and comparison for microbiome data in R. Brief Bioinform. 2020;1706:77.
Debourgogne A, Monpierre L, Sy KA, Valsecchi I, Decousser J-W, Botterel F. Interactions between bacteria and Aspergillus fumigatus in airways: from the mycobiome to molecular interactions. J Fungi (Basel). 2023;9:900.
pubmed: 37755008
doi: 10.3390/jof9090900
Briard B, Mislin GLA, Latgé J-P, Beauvais A. Interactions between Aspergillus fumigatus and pulmonary bacteria: current state of the field, new data, and future perspective. J Fungi (Basel). 2019. https://doi.org/10.3390/jof5020048 .
doi: 10.3390/jof5020048
pubmed: 31212791
pmcid: 6617096
Melloul E, Roisin L, Durieux M-F, Woerther P-L, Jenot D, Risco V, et al. Interactions of Aspergillus fumigatus and Stenotrophomonas maltophilia in an in vitro mixed biofilm model: does the strain matter? Front Microbiol. 2018. https://doi.org/10.3389/fmicb.2018.02850 .
doi: 10.3389/fmicb.2018.02850
pubmed: 30542331
pmcid: 6277776
Roisin L, Melloul E, Woerther P-L, Royer G, Decousser J-W, Guillot J, et al. Modulated response of Aspergillus fumigatus and Stenotrophomonas maltophilia to antimicrobial agents in polymicrobial biofilm. Front Cell Infect Microbiol. 2020;10: 574028.
pubmed: 33123497
pmcid: 7573239
doi: 10.3389/fcimb.2020.574028
O’Brien S, Fothergill JL. The role of multispecies social interactions in shaping Pseudomonas aeruginosa pathogenicity in the cystic fibrosis lung. FEMS Microbiol Lett. 2017. https://doi.org/10.1093/femsle/fnx128 .
doi: 10.1093/femsle/fnx128
pubmed: 28859314
pmcid: 5812498
Ostapska H, Le Mauff F, Gravelat FN, Snarr BD, Bamford NC, Van Loon JC, et al. Co-operative Biofilm Interactions between Aspergillus fumigatus and Pseudomonas aeruginosa through secreted galactosaminogalactan exopolysaccharide. J Fungi (Basel). 2022;8:336.
pubmed: 35448567
doi: 10.3390/jof8040336
Graeber SY, Mall MA. The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches. Lancet. 2023;402:1185–98.
pubmed: 37699417
doi: 10.1016/S0140-6736(23)01608-2
Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor–Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373:220–31.
pubmed: 25981758
pmcid: 4764353
doi: 10.1056/NEJMoa1409547
Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017;5:107–18.
pubmed: 28011037
doi: 10.1016/S2213-2600(16)30427-1
Harris JK, Wagner BD, Zemanick ET, Robertson CE, Stevens MJ, Heltshe SL, et al. Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutation. Ann Am Thorac Soc. 2020;17:212–20.
pubmed: 31604026
pmcid: 6993801
doi: 10.1513/AnnalsATS.201907-493OC
Graeber SY, Boutin S, Wielpütz MO, Joachim C, Frey DL, Wege S, et al. Effects of lumacaftor–ivacaftor on lung clearance index, magnetic resonance imaging, and airway microbiome in Phe508del homozygous patients with cystic fibrosis. Ann Am Thorac Soc. 2021;18:971–80.
pubmed: 33600745
doi: 10.1513/AnnalsATS.202008-1054OC
Frost FJ, Nazareth DS, Charman SC, Winstanley C, Walshaw MJ. Ivacaftor is associated with reduced lung infection by key cystic fibrosis pathogens. A cohort study using national registry data. Ann Am Thorac Soc. 2019;16:1375–82.
pubmed: 31319678
doi: 10.1513/AnnalsATS.201902-122OC
Heltshe SL, Mayer-Hamblett N, Burns JL, Khan U, Baines A, Ramsey BW, et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis. 2015;60:703–12.
pubmed: 25425629
doi: 10.1093/cid/ciu944
Bessonova L, Volkova N, Higgins M, Bengtsson L, Tian S, Simard C, et al. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax. 2018;73:731–40.
pubmed: 29748252
doi: 10.1136/thoraxjnl-2017-210394
Currie AJ, Main ET, Wilson HM, Armstrong-James D, Warris A. CFTR modulators dampen aspergillus-induced reactive oxygen species production by cystic fibrosis phagocytes. Front Cell Infect Microbiol. 2020;10:372.
pubmed: 32793514
pmcid: 7393064
doi: 10.3389/fcimb.2020.00372
Enaud R, Lussac-Sorton F, Charpentier E, Velo-Suárez L, Guiraud J, Bui S, et al. Effects of lumacaftor–ivacaftor on airway microbiota-mycobiota and inflammation in patients with cystic fibrosis appear to be linked to Pseudomonas aeruginosa chronic colonization. Microbiol Spectr. 2023;11: e0225122.
pubmed: 36971560
doi: 10.1128/spectrum.02251-22